492% in 1 hour from $0.42 to $2.49HUGE 🚀 +492% from $0.42 to $2.49 in 1 hour 🔥 NASDAQ:MBRX from halt to halt moves so wild the exchange had to pause trading to cool off a bit
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7.1222 USD
−21.76 M USD
0.00 USD
14.01 M
About Moleculin Biotech, Inc.
Sector
Industry
CEO
Walter V. Klemp
Website
Headquarters
Houston
Founded
2015
FIGI
BBG00B9T47L9
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.
MBRX Annamycin Fast Track and Orphan Drug Designation from FDAMoleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases.
the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to
Idea for next weeks, buy Possible Entry to make some money .
Volume is picking up.
Low float.
Support bounce, 2.06
Ressist 2.6
Position started 2.08
$MBRX Moleculin biotech $MBRX seems to have grit for sellThe Marketmiracle advisor reported last night a major entry on the stock $MBRX with a potential profit of 300% approximately
The company Moleculin Biotech has several active trials all in the field of cancer research and recently also against covid, has recently presented quarterly and annual data
MBRX - 100% Spike coming soon?I think that $3 is the honey spot here. If it goes this low there will likely be a nice 100% gain. It will likely drop to some degree then make up for it in the short term.
100% Survival Achieved in Osteosarcoma Lung MetastasesMoleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.
Computerized tomography (CT) scans demonstrated that animals treated with
$MBRX (fm @Marcoux)Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
$MBRX Potential Break Above 200ma Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the
Moleculin Announces Positive Interim Results in Pediatric Brain MBRX: Moleculin Biotech, Inc.
2020-10-01 07:30:00
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of MBRX is 1.0500 USD — it has increased by 8.61% in the past 24 hours. Watch Moleculin Biotech, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moleculin Biotech, Inc. stocks are traded under the ticker MBRX.
MBRX stock has risen by 12.98% compared to the previous week, the month change is a −8.63% fall, over the last year Moleculin Biotech, Inc. has showed a −78.03% decrease.
We've gathered analysts' opinions on Moleculin Biotech, Inc. future price: according to them, MBRX price has a max estimate of 20.00 USD and a min estimate of 4.00 USD. Watch MBRX chart and read a more detailed Moleculin Biotech, Inc. stock forecast: see what analysts think of Moleculin Biotech, Inc. and suggest that you do with its stocks.
MBRX reached its all-time high on Jun 6, 2016 with the price of 862.2000 USD, and its all-time low was 0.3975 USD and was reached on Feb 12, 2025. View more price dynamics on MBRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MBRX stock is 10.88% volatile and has beta coefficient of 2.89. Track Moleculin Biotech, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moleculin Biotech, Inc. there?
Today Moleculin Biotech, Inc. has the market capitalization of 13.42 M, it has increased by 10.95% over the last week.
Yes, you can track Moleculin Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Moleculin Biotech, Inc. is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
MBRX earnings for the last quarter are 0.25 USD per share, whereas the estimation was −1.28 USD resulting in a 119.48% surprise. The estimated earnings for the next quarter are −0.56 USD per share. See more details about Moleculin Biotech, Inc. earnings.
Moleculin Biotech, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MBRX net income for the last quarter is −1.88 M USD, while the quarter before that showed −10.59 M USD of net income which accounts for 82.23% change. Track more Moleculin Biotech, Inc. financial stats to get the full picture.
No, MBRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 22, 2025, the company has 17 employees. See our rating of the largest employees — is Moleculin Biotech, Inc. on this list?
Like other stocks, MBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moleculin Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moleculin Biotech, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moleculin Biotech, Inc. stock shows the sell signal. See more of Moleculin Biotech, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.